Jump to content

Developing RNA Therapeutics with the Genedata Biopharma Platform

Genedata Biopharma Partner Symposium, Basel, Switzerland
March 7, 2024

The unprecedented pace of development and the rapid deployment of mRNA-based vaccines during the pandemic demonstrated the efficacy and economic viability of RNA therapeutics. Beyond vaccines, RNA technology has potential in many therapeutic areas, for example enzyme-replacement therapy (ERT), immuno-oncology, and gene editing approaches. The widespread application of RNA technologies requires optimization of the RNA cargo and its delivery system which affects pharmacokinetics, tissue targeting, and therapeutic utility. However, comprehensive characterization and evaluation of a vast number of potential molecules and delivery systems is challenging and requires a specialized data infrastructure for efficient R&D. The Genedata Biopharma Platform enables timesaving capture and analysis of all data required to rapidly progress new RNA therapeutic candidates. The platform ensures data integrity, enables maximum workflow automation, and serves as an essential structured data foundation for AI/ML.

Request Resource

By submitting my data, I give consent to the collection, processing and use of my personal data in accordance with the Genedata privacy policy